Company: Nkarta Therapeutics
Job title: CSO
James Trager joined Nkarta Therapeutics, as Senior Vice President of R&D in 2016 and leads all discovery and development efforts. Nkarta is a South San Francisco based startup focused on the use of Natural Killer cells in the treatment of cancer. James is deeply versed in the development and application of cellular therapies for cancer, with broad exposure from discovery to development, quality control, manufacturing, clinical application and regulatory issues surrounding these complex therapies. He previously served as Vice President of Research and Development at Dendreon, where he was responsible for product development, clinical immunology, and analytical development, supporting the late stage development of sipuleucel-T through clinical study, approval, and commercialization. Prior to Dendreon, James was a Senior Scientist at Geron; he was part of the team that cloned human telomerase, and later established a Quality Control function for the manufacture and clinical development of a telomerase inhibitor.
James is a graduate of St. John’s College in Santa Fe New Mexico; and served as a Peace Corps volunteer in the Central African Republic. He received his doctorate in Molecular Biology and Biochemistry from the University of California at Berkeley, where he performed mechanistic studies on the src oncogene.
Maximizing the Potential of NK Cells for Therapeutic Application 4:10 pm
Discussing challenges in the expansion and engineering of NK cells Genetic manipulation of NK cells to enhance tumor targeting and overcome tumor microenvironment Highlighting the potential of combining NK and T cells for therapeutic synergyRead more
day: Day Two